Zacks Research Downgrades SAB Biotherapeutics Stock to Strong Sell

Analysts cite concerns over the company's earnings and financial performance.

Mar. 14, 2026 at 11:40am

Got story updates? Submit your updates here. ›

Zacks Research has downgraded SAB Biotherapeutics (NASDAQ:SABS) from a 'hold' rating to a 'strong sell' rating, citing the company's disappointing financial results and earnings outlook. Other analysts have also issued mixed ratings on the stock, with some maintaining a 'buy' recommendation while others have assigned 'sell' ratings.

Why it matters

The downgrade by Zacks Research, a prominent investment research firm, could negatively impact investor sentiment and the stock price of SAB Biotherapeutics, a clinical-stage biotechnology company focused on developing polyclonal antibody therapeutics. The mixed analyst ratings and concerns over the company's financial performance may raise questions about its long-term prospects and ability to execute on its strategic goals.

The details

In its research report, Zacks Research cited SAB Biotherapeutics' recent quarterly earnings results, which missed analysts' consensus estimates. The company reported a loss of $0.46 per share, significantly higher than the expected loss of $0.16 per share. Other analysts have also issued mixed ratings on the stock, with Chardan Capital lifting its price target but Wall Street Zen and Weiss Ratings assigning 'sell' ratings. The company's lead programs are focused on developing treatments for infectious diseases using its proprietary Tc Bovine® platform.

  • SAB Biotherapeutics reported its latest quarterly earnings results on March 9, 2026.
  • Zacks Research issued its downgrade on March 14, 2026.

The players

Zacks Research

A prominent investment research firm that provides analysis and ratings on publicly traded companies.

SAB Biotherapeutics

A clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics using its proprietary Tc Bovine® platform.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The downgrade of SAB Biotherapeutics by Zacks Research highlights the challenges facing the company as it seeks to develop and commercialize its innovative polyclonal antibody therapies. The mixed analyst ratings and concerns over the company's financial performance underscore the need for SAB to demonstrate strong execution and deliver on its strategic goals to regain investor confidence.